'On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has declined 1.16% to Rs 805.17 crore. Operating profit margin has jumped from 28.30% to 31.20%, leading to 8.96% rise in operating profit to Rs 251.20 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 16.65% to 14.59%. Purchase of finished goods cost rose from 20.80% to 26.44%. Employee cost decreased from 18.22% to 17.39%. Other expenses fell from 16.57% to 12.95%.
Other income rose 22.67% to Rs 43.72 crore. PBIDT rose 10.80% to Rs 294.92 crore. Provision for interest rose 13.51% to Rs 0.42 crore.
PBDT rose 10.79% to Rs 294.5 crore. Provision for depreciation fell 5.42% to Rs 15.52 crore.
Profit before tax grew 1...
Pleaselogin & subscribe to view the full report.
More Reports
|
|